- Home
- NRGV vs CHRS Comparison
NRGV vs CHRS Comparison
Compare NRGV & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRGV
- CHRS
- Stock Information
- Founded
- NRGV 2017
- CHRS 2010
- Country
- NRGV United States
- CHRS United States
- Employees
- NRGV N/A
- CHRS N/A
- Industry
- NRGV Industrial Machinery/Components
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NRGV Miscellaneous
- CHRS Health Care
- Exchange
- NRGV Nasdaq
- CHRS Nasdaq
- Market Cap
- NRGV 133.4M
- CHRS 159.2M
- IPO Year
- NRGV N/A
- CHRS 2014
- Fundamental
- Price
- NRGV $2.29
- CHRS $1.29
- Analyst Decision
- NRGV Buy
- CHRS Strong Buy
- Analyst Count
- NRGV 3
- CHRS 4
- Target Price
- NRGV $1.58
- CHRS $4.51
- AVG Volume (30 Days)
- NRGV 2.0M
- CHRS 1.3M
- Earning Date
- NRGV 11-11-2025
- CHRS 11-05-2025
- Dividend Yield
- NRGV N/A
- CHRS N/A
- EPS Growth
- NRGV N/A
- CHRS N/A
- EPS
- NRGV N/A
- CHRS 1.55
- Revenue
- NRGV $51,716,000.00
- CHRS $272,209,000.00
- Revenue This Year
- NRGV $314.58
- CHRS N/A
- Revenue Next Year
- NRGV $39.00
- CHRS $126.00
- P/E Ratio
- NRGV N/A
- CHRS $0.83
- Revenue Growth
- NRGV N/A
- CHRS 52.33
- 52 Week Low
- NRGV $0.60
- CHRS $0.66
- 52 Week High
- NRGV $2.70
- CHRS $2.43
- Technical
- Relative Strength Index (RSI)
- NRGV 70.49
- CHRS 62.30
- Support Level
- NRGV $1.73
- CHRS $1.26
- Resistance Level
- NRGV $2.33
- CHRS $1.40
- Average True Range (ATR)
- NRGV 0.18
- CHRS 0.08
- MACD
- NRGV 0.00
- CHRS 0.00
- Stochastic Oscillator
- NRGV 94.12
- CHRS 64.52
About NRGV Energy Vault Holdings Inc.
Energy Vault Holdings Inc is a grid-scale energy storage company that is driving a faster transition to renewable power by solving the intermittence issues that are inherent to the prevalent sources of renewable energy, solar and wind. Geographical presence in United States, China and Other. Majority of its revenue comes from U.S.
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.